Synthesis and antiproliferative activity of [1,2,4] triazino[4,3-a]indoles

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 3775-3779

  Barraja, Paola ^a   Diana, Patrizia ^a   Lauria, Antonino ^a   Montalbano, Alessandra ^a   Almerico, Anna Maria ^a   Dattolo, Gaetano ^a   Cirrincione, Girolamo ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Dipto Farmacochim Tossicol/Biol   (Italy)

Author keywords

2 Diazoindoles; Antiproliferative activity; Triazinoindoles

Indexed keywords

2 DIAZO 3 ETHOXYCARBONYLINDOLE; ANTINEOPLASTIC AGENT; AZO COMPOUND; CARBENE; CARBONYL DERIVATIVE; DIETHYL 4 IMINO 1,4 DIHYDRO 1,2,4 TRIAZINO[4,3 A]INDOLE 3,10 DICARBOXYLATE; ETHYL 3 (AMINOCARBONYL) 4 IMINO 1,4 DIHYDRO 1,2,4 TRIAZINO[4,3 A]INDOLE 10 CARBOXYLATE; ETHYL 3 ACETYL 4 HYDROXY 4 METHYL 1,4 DIHYDRO 1,2,4 TRIAZINO[4,3 A]INDOLE 10 CARBOXYLATE; ETHYL 3 CYANO 4 IMINO 1,4 DIHYDRO 1,2,4 TRIAZINO[4,3 A]INDOLE 10 CARBOXYLATE; INDOLE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMICAL REACTION; CONCENTRATION RESPONSE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUANTUM YIELD; STRUCTURE ACTIVITY RELATION; DRUG SCREENING; NEOPLASM; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; NEOPLASMS; TRIAZINES;

EID: 14944345007     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cirrincione G, Almerico AM, Diana P, Grimaudo S, Barraja P, Mingoia F, Dattolo G and Aiello E: 2-Diazopyrroles: synthesis and antileukemic activity. Il Farmaco 51: 275-277, 1996.
2. Barraja P, Diana P, Lauria A, Almerico AM, Dattolo G and Cirrincione G: 2-Diazo-2H-indoles. Helv Chim Acta 84: 2212-2219, 2001.
3. a) Lucas US and Huang AT: Clinical management of melanoma. In: Development in Oncology; Siegler HF ed; Martinus Nijhoff: The Hague 5: 382, 1982;
4. b) Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanin M, Devizzi L, Soncini F and Valagussa P: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten year results. J Clin Oncol 14: 1421-1430, 1996.
5. Diana P, Barraja P, Lauria A, Almerico AM, Cirrincione G, Loi AG, Congeddu E, Musiu C, Putzolu M and La Colla P: 2-Triazenopyrroles: synthesis and biological activity. Eur J Med Chem 34: 353-360, 1999.
6. Barraja P, Diana P, Lauria A, Montalbano A, Almerico AM, Dattolo G and Cirrincione G: 2-Triazenoindoles: synthesis and biological activity. Anticancer Res 22: 837-840, 2002.
7. Diana P, Barraja P, Lauria A, Almerico AM, Dattolo G and Cirrincione G: Pyrrolo[2,1-d][1,2,3,5]tetrazinones, a new class of azolotetrazines related to the antitumor drug temozolomide. Synthesis: 2082-2086, 1999.
8. a) Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT and Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rep 23: 35-61, 1997;
9. b) Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M and Stevens MFG: Cancer research campaign phase II trial of temozolomide in metabolic melanoma. J Clin Oncol 13: 910-914, 1995;
10. c) O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illinworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P and Stevens MFG: Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 29A: 940-943, 1993;
11. d) Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH and Gibson AC: Phase I trial of temozolomide (CCRG81045M&B39831: NSC362856). Br J Cancer 65: 287-291, 1992.
12. Diana P, Barraja P, Lauria A, Almerico AM, Dattolo G and Cirrincione G: Pyrrolo[2,1-d][1,2,3,5]tetrazine-4-(3H)-ones, a new class of azolotetrazines with potent antitumor activity. Bioorg Med Chem Lett 11: 2371-2380, 2003.
13. Diana P, Barraja P, Lauria A, Almerico AM, Montalbano A, Dattolo G and Cirrincione G: Pyrrolo[2,1-c][1,2,4]triazines from 2-diazopyrroles: synthesis and antiproliferative activity. Eur J Med Chem 37: 267-272, 2002.
14. a) Neunhoeffer H: 1,2,4-Triazines and their benzoderivatives. In: Comprehensive Heterocyclic Chemistry; Katritzky AR ed; Pergamon Press Oxford 3: 385-456, 1984;
15. b) Neunhoeffer H: 1,2,3-Triazines. In: Chemistry of Heterocyclic Compounds; Neunhoeffer H and Wiley PF eds 33: 189-574, 1978.
16. Partridge MW and Stevens MFG: Pyrazolo-as-triazines.I. J Chem Soc (C): 1127-1131, 1966.
17. Cirrincione G, Almerico AM, Aiello E and Dattolo G: Diazoazoles. Adv Heterocycl Chem 48: 65-175, 1990.
18. Baig GU and Stevens MFG: Triazine and related products. Part 22. Synthesis and reactions of imidazo[5,1-c][1,2,4]triazines. J Chem Soc Perkin I: 1424-32, 1981.
19. a) Grever MR, Sherpatz SA and Chabner BA: The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19: 622-638,1992;
20. b) Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langely J, Cronise P, Vaigro-Woiff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd MR: Feasibility of a high-flux anticancer drug screen using a diverse panel cultured human tunor cell lines. J Natl Cancer Inst 83: 757-766, 1991;
21. c) Boyd NR, Paull KD and Rubinstein LV: Data display and analysis strategies for the new NCI disease-oriented in-vitro anti-tumor drug screen. In: Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development; Valeriote FA, Corbett TH and Baker LH eds., Kluwer Academic Publ., Norwell, Mass., 11-34, 1992.
22. Paull K, Shoemaker R, Hodes L, Monks A, Scudiero D, Rubistein L, Plowman J and Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092, 1989.